Quick Facts
- Policy Date: On October 13, 2023, CMS officially removed the restrictive National Coverage Determination for beta-amyloid PET scans.
- Scan Limit: The restrictive once-per-lifetime limit has been eliminated, allowing for repeat scans to monitor disease progression.
- Eligibility Criteria: Patients must demonstrate Mild Cognitive Impairment or mild dementia with MMSE or MoCA scores typically between 24 and 30.
- Prerequisites: A brain MRI is required within 12 months prior to the PET scan to rule out other structural issues.
- Average Cost: National Medicare reimbursement is approximately $1,370 to $1,550, though out-of-pocket costs vary by region.
- Primary Purpose: Used primarily to confirm the presence of beta-amyloid plaques and determine if a patient qualifies for anti-amyloid medications.
CMS has officially expanded Medicare PET scan coverage for Alzheimer’s, removing the restrictive once-per-lifetime limit to support early detection and treatment. This policy shift allows clinicians to use amyloid-targeting radiopharmaceutical tracers to confirm a diagnosis of Alzheimer's disease or Mild Cognitive Impairment, facilitating faster access to modern monoclonal antibody treatments.
Medicare Amyloid PET Scan Eligibility: Who Qualifies?
Navigating the healthcare system requires understanding the specific clinical thresholds that trigger coverage. For a patient to meet the Medicare amyloid PET scan eligibility requirements, they must first show signs of cognitive decline that are documented by a healthcare professional. This expansion is not intended for general screening of asymptomatic individuals but for those already experiencing Mild Cognitive Impairment or early-stage dementia.
The medical necessity is often validated through standardized cognitive assessments. Medicare PET scan coverage generally applies to patients scoring between 24 and 30 on the Mini-Mental State Exam (MMSE) or the Montreal Cognitive Assessment (MoCA). These scores indicate that the patient is in the early stages of the disease where anti-amyloid medications are most effective.
Furthermore, CMS PET scan coverage for dementia requires a preliminary diagnostic step: a brain MRI must have been performed within the last 12 months. This ensures that the cognitive symptoms aren't being caused by other visible issues like tumors or major strokes. While previous rules often required cerebrospinal fluid (CSF) testing before an imaging scan, current Medicare PET scan coverage for Alzheimer's allows the PET scan to serve as a primary biomarker validation tool.
Final determinations on individual cases are now handled by local Medicare Administrative Contractors (MACs). This means that while the national "once-in-a-lifetime" ban is gone, your specific steps to get Medicare approval for Alzheimer's PET scan may vary slightly depending on your geographic location. Patients should work closely with their neurologists to ensure all local MAC documentation requirements are met to avoid unexpected denials.
Clinical Eligibility Checklist
- Cognitive Diagnosis: Documented Mild Cognitive Impairment (MCI) or mild dementia.
- Cognitive Scores: MMSE or MoCA score between 24 and 30.
- Imaging History: Brain MRI completed within the previous 12 months.
- Treatment Context: Evaluation for or monitoring of FDA-approved anti-amyloid therapies.
Comparing Scans: FDG PET vs. Amyloid PET for Alzheimer's
It is important for patients and caregivers to distinguish between the two primary types of neuroimaging used in dementia care. For years, Medicare has provided coverage for FDG PET scans, which measure glucose metabolism in the brain. While FDG PET is excellent at identifying neurodegeneration and distinguishing between different types of dementia (like frontal-temporal dementia versus Alzheimer's), it does not look for the specific physical markers of Alzheimer's.
In contrast, amyloid PET scans use specialized radiopharmaceutical tracers to bind to beta-amyloid plaques. Identifying these plaques is the "gold standard" for an Alzheimer's diagnosis. This distinction has become vital because newer monoclonal antibody treatments are specifically designed to clear these plaques. Without a scan confirming the presence of amyloid, a patient cannot safely or effectively begin these new therapies.
The clinical value of this imaging is backed by significant data. The IDEAS study, which tracked more than 18,000 patients, found that amyloid PET scans led to a change in medical management in 60% of cases. Furthermore, the scan resulted in a diagnostic change for approximately 35% of patients after the imaging was reviewed. This high rate of diagnostic accuracy is why the removal of the lifetime cap is a landmark shift for longevity and preventive care.
| Feature | FDG PET Scan | Amyloid PET Scan |
|---|---|---|
| What it measures | Brain metabolic activity (glucose use) | Physical buildup of beta-amyloid plaques |
| Primary Use | Detecting neurodegeneration | Confirming Alzheimer's biomarkers |
| Medicare Status | Covered for differential diagnosis | Expanded coverage for diagnosis & treatment |
| Key Benefit | Rules out other dementia types | Required for anti-amyloid drug eligibility |
| Medicare coverage for FDG PET vs amyloid PET scan | Widely available for many years | Recently expanded (Oct 2023) |
Financial Breakdown: Costs and Medicare Part B Details
Understanding the out of pocket cost for PET scan with Medicare for Alzheimer's is essential for financial planning. Because these scans are typically performed in an outpatient setting, they fall under Medicare Part B. Generally, after you meet your annual Part B deductible, Medicare pays 80% of the approved amount, leaving the patient responsible for the remaining 20% coinsurance.
Historically, these scans were a major financial burden, with an out of pocket cost for PET scan with Medicare for Alzheimer's often exceeding $3,000 or more when insurance coverage was denied. Under the new rules, the base reimbursement for the scan itself ranges from $1,370 to $1,550, plus the cost of the radiopharmaceutical tracers.
There is also a significant change coming to how these tracers are billed. Starting in 2026, CMS plans to "unbundle" the payment for diagnostic radiopharmaceuticals that cost more than $655 per day. This means that instead of a flat fee for the whole procedure, Medicare will pay separately for the expensive tracers like Amyvid (A9586), Vizamyl (Q9982), and Neuraceq (Q9983). This change is expected to improve patient access by ensuring that imaging centers are fairly reimbursed for the high costs of these specialized chemicals.
For those on Medicare Advantage plans, coverage must be at least as comprehensive as Original Medicare. However, you may need to use specific in-network facilities. Always verify the Medicare PET scan coverage for monoclonal antibody treatments with your plan provider before scheduling the appointment, as some may require prior authorization.
Coding and Billing Sidebar: 2026 Updates
- Current Bundle: Tracers are currently included in the overall procedure payment.
- 2026 Shift: Radiopharmaceuticals costing over $655 will be paid separately.
- HCPCS Codes: Keep an eye on codes A9586, Q9982, and Q9983 on your billing statements to ensure correct tracer reimbursement.
FAQ
Does Medicare cover PET scans for dementia diagnosis?
Yes, Medicare covers PET scans for dementia diagnosis under specific conditions. Traditionally, FDG PET scans were covered to help distinguish between different types of dementia. As of October 2023, Medicare has significantly expanded coverage to include amyloid PET scans, which are used to identify the physical plaques associated with Alzheimer's disease in patients showing signs of cognitive decline.
What conditions are covered for PET scans under Medicare?
Medicare covers PET scans for a variety of conditions, including many types of cancer, certain heart conditions, and now, Alzheimer's disease and Mild Cognitive Impairment. For brain health, the scan must be deemed medically necessary to confirm a diagnosis or to determine if a patient is an appropriate candidate for specific FDA-approved treatments, such as monoclonal antibody therapies.
How many PET scans does Medicare cover in a lifetime?
Under the new 2023 regulations, the previous once-per-lifetime limit for amyloid PET scans has been removed. There is no longer a hard cap on how many PET scans does Medicare cover for Alzheimer's. Instead, the frequency is determined by medical necessity. This allows doctors to use subsequent scans to monitor how a patient is responding to treatment or to track the progression of beta-amyloid plaques over time.
What is the out-of-pocket cost for a PET scan with Medicare?
The out-of-pocket cost typically consists of the 20% Part B coinsurance after the annual deductible has been met. While the total cost of an amyloid PET scan can exceed $3,000, the Medicare-approved amount is usually lower. Patients with supplemental insurance (Medigap) may find that their 20% responsibility is fully or partially covered, significantly reducing their out-of-pocket expenses.
Is a PET scan covered by Medicare Part B?
Yes, PET scans are covered under Medicare Part B because they are considered a diagnostic outpatient service. To ensure coverage, the scan must be ordered by a physician and performed at a facility that accepts Medicare. Because coverage is now managed by local Medicare Administrative Contractors, it is always a good idea to have your doctor's office verify the specific billing requirements for your region.
